'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Cipla has increased 7.10% to Rs 7072.97 crore. Sales of Phamaceuticals segment has gone up 6.49% to Rs 6,777.84 crore (accounting for 95.21% of total sales). Sales of New Ventures segment has gone up 21.67% to Rs 341.30 crore (accounting for 4.79% of total sales). Inter-segment sales rose Rs 41.76 crore to Rs 46.17 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 13.66% to Rs 1,930.73 crore. PBIT of Phamaceuticals segment rose 10.75% to Rs 1,888.86 crore (accounting for 97.83% of total PBIT). PBIT of New Ventures reported profit of Rs 41.87 crore compared to loss of Rs 6.86 crore.
PBIT margin of Phamaceuticals segment rose from 26.80% to 27.87%. PBIT margin of New Ventures segment rose f...
Pleaselogin & subscribe to view the full report.
More Reports
-
(05-May-2025)
Epigral
Capex in FY2025 was Rs 195 crore
-
(05-May-2025)
Voltamp Transformers
Growth in net restricted to 4% hit by lower OPM, lower OI and higher taxation
-
(05-May-2025)
Kotak Mahindra Bank
Better margins and asset quality, loan growth moderates
-
(04-May-2025)
State Bank of India
Profit declines on high provisions, asset quality remains healthy
|
|